AI brief of an SEC Form 8-K · Dexcom (DXCM)

DexCom posts 2025 revenue of about $4.662 billion and guides 2026 to $5.16-$5.25 billion

Positive Impact 3 of 5 earnings Written later

DexCom reported preliminary, unaudited revenue of about $4.662 billion for fiscal 2025, up 16% from 2024, and about $1.260 billion for the fourth quarter, up 13%. It also gave an initial 2026 total revenue outlook of $5.16-$5.25 billion, growth of about 11-13%, with non-GAAP gross and operating margin targets, and said audited results will follow on February 12, 2026.

Key points

  • Fourth-quarter 2025 revenue of about $1.260 billion, up 13%: U.S. about $892 million (up 11%), international about $368 million (up 18%)
  • Fiscal 2025 preliminary revenue of about $4.662 billion, up 16%, which the company says exceeded the high end of its guidance
  • 2026 outlook: total revenue of $5.16-$5.25 billion, non-GAAP gross profit margin of about 63-64% and non-GAAP operating margin of about 22-23%
  • 2025 margin guidance reiterated at about 61% non-GAAP gross margin and 20-21% non-GAAP operating margin; audited results due February 12, 2026

The filing

CompanyDexcom (DXCM)
Form8-K, current report
Filed with the SECJan 12, 2026, 7:30 AM ET
Accession number0001093557-26-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.